GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BIOGY) » Definitions » Gross Profit

BioGaia AB (BioGaia AB) Gross Profit : $89.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Gross Profit?

BioGaia AB's gross profit for the three months ended in Mar. 2024 was $25.5 Mil. BioGaia AB's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $89.8 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BioGaia AB's gross profit for the three months ended in Mar. 2024 was $25.5 Mil. BioGaia AB's Revenue for the three months ended in Mar. 2024 was $35.5 Mil. Therefore, BioGaia AB's Gross Margin % for the quarter that ended in Mar. 2024 was 71.89%.

BioGaia AB had a gross margin of 71.89% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of BioGaia AB was 75.34%. The lowest was 69.65%. And the median was 73.25%.


BioGaia AB Gross Profit Historical Data

The historical data trend for BioGaia AB's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Gross Profit Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.79 65.40 64.13 77.27 92.63

BioGaia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.06 21.03 21.28 21.97 25.53

Competitive Comparison of BioGaia AB's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Gross Profit distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Gross Profit falls into.



BioGaia AB Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BioGaia AB's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=126.395 - 33.762
=92.6

BioGaia AB's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=35.519 - 9.986
=25.5

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $89.8 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BioGaia AB's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=25.5 / 35.519
=71.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BioGaia AB  (OTCPK:BIOGY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioGaia AB had a gross margin of 71.89% for the quarter that ended in Mar. 2024 => Durable competitive advantage


BioGaia AB Gross Profit Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (BioGaia AB) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.